At present, only ramucirumab (VEGFR-targeting) has been approved as a second-line treatment for EAC, and trastuzumab deruxtecan (HER2-targeting) has been approved as a first-line treatment in combination with chemotherapy in HER-2-positive gastric cancer and gastroesophageal adenocarcinoma patients [6]. This evidence concerns the gene ERBB2 and gastric cancer.